Eli Lilly and Company reported Q1 2026 earnings topping estimates, with revenue reaching $19.80 billion and a normalized EPS of $8.55, showcasing a notable 25.90% surprise. Amid a 7.9% stock decline this year, the company has seen a 32.30% increase in share value over time, driven by positive clinical trial results and expanded partnerships, including a $2.75 billion deal with Insilico Medicine. Furthermore, the acquisitions of Centessa Pharmaceuticals for $6.3 billion and plans to acquire Kelonia Therapeutics for $7 billion signal a strategic push to dominate the diabetes and obesity markets.
“Eli Lilly And Co · Q1 2026 Normalized EPS · estimate · 8.55”
“Eli Lilly And Co · Q1 2026 Revenue · estimate · 19.80B”
“Eli Lilly And Co · Revenue · Q1 2026 · 19.80B”
“Eli Lilly And Co · Q1 2026 EPS surprise · percentage · +25.90%”
“Eli Lilly And Co · Q1 2026 Revenue surprise · percentage · +11.25%”
“Eli Lilly And Co · Q1 2026 Normalized EPS · actual · 8.55”
“Insilico Medicine · expanded its partnership with · Eli Lilly · up to $2.75 billion”
“Eli Lilly and Company · is · a leader in the diabetes and obesity market · true”
“Lilly’s stock · has declined · 7.9% so far this year · true”
“Lilly’s shares · currently trade at · 25.46 forward earnings · true”
“LLY · holds the first position in · the State Street Health Care Select Sector SPDR ETF XLV · 14.81% weightage”
“LLY · holds the first position in · the iShares U.S. Pharmaceuticals ETF IHE · 22.28% weightage”
